Objective: Neoadjuvant "long-course" chemoradiation is considered a standard of care in locally advanced rectal cancer. In addition to prostatectomy, external beam radiotherapy and brachytherapy with or without androgen suppression (AS) are well established in prostate cancer management. A retrospective review of ten cases was completed to explore the feasibility and safety of applying these standards in patients with dual pathology. To our knowledge, this is the largest case series of synchronous rectal and prostate cancers treated with curative intent. Methods: Eligible patients had synchronous histologically proven locally advanced rectal cancer (defined as cT3-4Nx; cTxN1-2) and non-metastatic prostate cancer (pelvic nodal disease permissible). Curative treatment was delivered to both sites simultaneously. Follow-up was as per institutional guidelines. Acute and late toxicities were reviewed, and a literature search performed. Results: Pelvic external beam radiotherapy (RT) 45-50.4 Gy was delivered concurrent with 5-fluorouracil (5FU). Prostate total dose ranged from 70.0 to 79.2 Gy. No acute toxicities occurred, excluding AS-induced erectile dysfunction. Nine patients proceeded to surgery, and one was managed expectantly. Three relapsed with metastatic colorectal cancer, two with metastatic prostate cancer. Five patients have no evidence of recurrence, and four remain alive with metastatic disease. With a median follow-up of 2.2 years (range 1.2-6.3 years), two significant late toxicities occurred; G3 proctitis in a patient receiving palliative bevacizumab and a G3 anastomotic stricture precluding stoma reversal. Conclusion: Patients proceeding to synchronous radical treatment of both primary sites should receive 45-50.4 Gy pelvic RT with infusional 5FU. Prostate dose escalation should be given with due consideration to the potential impact of prostate cancer on patient survival, as increasing dose may result in significant late morbidity. Review of published series explores the possibility of prostate brachytherapy as an alternative method of boost delivery. Frequent use of bevacizumab in metastatic rectal cancer may compound late rectal morbidity in this cohort. Advances in knowledge: To our knowledge, this is the largest case series of synchronous rectal and prostate cancers treated with curative intent. This article contributes to the understanding of how best to approach definitive treatment in these patients.
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INTRODUCTION
Prostate and colorectal cancers are the two most common cancers in males with 3014 and 1389 new cases diagnosed in Ireland per year, respectively. 23% of colorectal primaries are rectal in origin. 1 There are limited reports of the curative management of synchronous prostate and rectal cancers. Neoadjuvant "long-course" chemoradiation (NACRT) and "short-course" external beam radiotherapy (EBRT) are considered standards of care in locally advanced rectal cancer. 2, 3 In addition to prostatectomy, EBRT and brachytherapy with or without androgen deprivation therapy (ADT) are firmly established in the treatment of prostate cancer. A retrospective review of ten cases treated with radical intent was completed to explore the feasibility and safety of applying these standards to patients with synchronous dual pathology.
METHODS AND MATERIALS
Data were retrospectively collected from ten patients treated in three centres: St Luke's Radiation Oncology Network, Dublin; University College Hospital Galway; and Cork University Hospital, Dublin. For inclusion, all patients met the following criteria: dual diagnosis of locally advanced rectal (defined as cT3-4Nx; cTxN1-2) and non-metastatic prostate cancer (pelvic nodal disease attributed to prostate cancer permissible); both tumours histologically confirmed by an endoscopic rectal biopsy and either a trans-rectal or trans-perineal prostate biopsy; serum baseline prostate-specific antigen (PSA); clinical staging with digital rectal examination, rigid sigmoidoscopy, pelvic MRI ( Figure 1 ); discussion at a multidisciplinary meeting and curative treatment delivered for both cancers simultaneously. Metastatic disease was excluded by isotope bone scan. MRI staging influenced overall staging if evidence of extracapsular extension or seminal vesicle (SV) invasion was detected. Patients were followed up according to institutional guidelines for both cancers. Patient toxicity during radiotherapy (RT) was assessed on treatment by medical and/or nursing staff and documented in medical notes and recreated retrospectively using the National Cancer Institute common terminology criteria of adverse events v. 4.0 grading sheets for both acute and late genitourinary and gastrointestinal toxicities. Metastatic relapse was determined on interval CT scanning of the thorax, abdomen and pelvis. Descriptive statistics were used to analyse the data in light of the retrospective nature of this review. Table 1 . Median follow-up is 2.2 years from initial diagnosis (range 1.18-6.34 years). The median age in our patient cohort was 68 years (range 47-79 years). All cases had locally advanced rectal cancer. Patients 1 and 4 had low rectal tumours (0-5 cm from anal verge). Patients 3, 5, 6, 9 and 11 had mid-rectal tumours (6-10cm), and Patients 2, 7 and 8 had upper rectal tumours (11-15 cm ). Prostate histology revealed Gleason scores ranging from 5 (3 1 2) to 9 (5 1 4). Rectal biopsies showed grade 2 adenocarcinoma in all cases except for Patient 10 in whom high-grade dysplasia was seen. This was discordant with MRI appearances of the primary rectal cancer and is included in our cohort, as the multidisciplinary meeting concluded there to be adequate diagnostic information to safely assume this was an adenocarcinoma. Patients 1, 7, 8 and 9 were prescribed combined androgen blockade at diagnosis. Patients 1 and 7 were treated as node-positive prostate cancer, without histological confirmation, and were prescribed life-long ADT.
RESULTS

Patient characteristics and treatment details are summarized in
All patients were CT simulated in the supine or prone positions. When prone, additional immobilization was achieved with a bellyboard. The use of bladder filling or rectal preparation was not standardized across patients; bladder filling alone (Patients 6, 7 and 10), rectal preparation and bladder filling Table 2 ).
Nine of the ten patients proceeded to surgery. Patient 8 declined surgery and had expectant management. The majority underwent anterior resection (AR). An abdominoperineal resection (APR) was performed for Patient 6. Patient 1 underwent pelvic exenteration involving rectal resection and cystoprostatectomy with formation of an intestinal urinary conduit 13 months post CRT. In the latter case, a residual rectal ulcer was 4 Gy to the pelvis followed by caesium-137 ( 131 Cs) implantation after a 4-to 5-week interval from the end of EBRT. Brachytherapy boosts ranged from 80 to 90 Gy. Rectal cancer surgery was performed after an interval ranging from 5 weeks to 2 months; all patients underwent AR. One patient experienced a grade 3 GI toxicity. 5 Kavanagh et al 6 published a treatment paradigm for all patients presenting with synchronous rectal and prostate cancers inclusive of those with metastatic disease at diagnosis. Five patients in their cohort received radical treatment; one patient had a prostatectomy followed by neoadjuvant CRT and AR; the remaining four patients were treated similarly to our cohort with shrinking field RT, chemotherapy and surgery with the only reported morbidity being post-operative wound infections in two patients. Siu et al 7 in Stanford (Stanford, CA) have documented their management of two medically inoperable patients. One received CRT; 50.4 Gy with concurrent 5FU followed by a second phase delivering a total dose of 60.4 Gy to the prostate. The second patient received 45 Gy to the pelvis with a 20-Gy boost to the prostate. With 1 and 2 years follow-up, respectively, both patients were alive with PSA readings ,1.0 ng ml 21 and no rectal cancer recurrence. Two further case reports document the delivery of multiple-phase neoadjuvant RT and concomitant 5FU, including the use of hypofractionated RT to the prostate. The patient treated with hypofractionation experienced grade 2 enteritis. 8, 9 Primary surgical management with radical retropubic prostatectomy and AR or APR has been described in two separate case series. 10, 11 When faced with a patient with synchronous rectal and prostate cancers, the validity of treating both sites must be questioned on an individual patient basis. Many prostate cancers will not be clinically relevant in a patient's lifetime. For lower risk prostate cancers, older patients or where a patient's life expectancy is likely to be limited by a high-risk rectal cancer and/or comorbidities, it may be difficult to justify a prostate boost. Locally advanced rectal cancer in which NACRT is considered are by definition staged as IIIB for which reported 5-year overall survival (OS) is 30-60%. Disease-specific survival in low-and intermediate-risk prostate cancers ranges from 75% to 86% and 34% in high-risk disease. 12 Proceeding with neoadjuvant treatment of a rectal cancer in isolation without addressing the known prostate cancer could in the event of prostate cancer progression complicate further RT delivery. Salvage surgery would be challenging in a previously irradiated pelvis. Experience from salvage prostatectomy after EBRT for prostate cancer reports increased morbidity compared with primary prostatectomy, as tissue planes become difficult to traverse secondary to fibrosis and scarring. Two series report rates between 22% and 30% for bladder neck contractures and rectal injury as high as 25%. 13 However, these considerations are tempered by the reality that a proportion of patients treated will relapse with metastatic rectal cancer.
Applying standards of care for rectal and prostate cancer in patients diagnosed with synchronous tumours is achievable with NACRT and a prostate boost. A prostate boost can be delivered by EBRT or brachytherapy. We recommend for appropriate patients proceeding to synchronous radical treatment of both primary sites that all patients should receive pelvic CRT with infusional 5FU as standard. Pelvic doses of 45-50.4 Gy in 1.8 Gy per fraction or 50 Gy in 2 Gy per fraction are feasible as demonstrated in our series.
Dose escalation to the prostate should be addressed with due consideration to the potential impact of prostate cancer on patient's estimated OS and in the knowledge that increasing dose may result in significant late morbidity. An increased incidence of GI toxicity in higher dose groups has been reported in randomized control trials examining dose escalation in prostate cancer, [14] [15] [16] and its incidence is strongly correlated to the volume of rectum receiving .70 Gy. 15 Ultimately, GI toxicity is a function of technique, dose, treated volume and reported end point. A lower EBRT boost to the prostate would minimize GI toxicity because in the absence of a demonstrable OS benefit from dose escalation, it may be difficult to justify higher doses to the prostate in light of potential dose-dependent toxicity. Most importantly, we recommend that any prostate boost be considered and justified in light of patient age and comorbidity, likelihood of future metastatic rectal cancer and risk category of prostate cancer.
The potential for rectal toxicity resulting from the interaction between the high-dose boost region and (future) bevacizumab should be considered when planning synchronous strategies, especially for patients with higher-risk rectal cancer. This was doubtless the aetiology of rectal ulceration for Patient 2. In a prospective observational cohort study Sugrue et al 17 noted previous pelvic radiotherapy as a baseline characteristic present in the majority of patients with metastatic colorectal cancer receiving bevacizumab plus first-line chemotherapy with evidence of GI perforation; however, this did not reach statistical significance. 18 Investigators in the Mayo Clinic confirmed this risk of serious bowel injury (SBI) for patients receiving both RT and vascular endothelial growth factor inhibitor (VEGFI) therapy. In 76 patients treated with abdominal stereotactic body radiation therapy (SBRT) to a median dose of 50 Gy in 5 fractions only patients who had received VEGFI therapy before SBRT experienced SBI. A statistically significant correlation between SBI and VEGFI therapy within 3 months of SBRT was demonstrated. 19 The majority of patients with metastatic rectal cancer will receive bevacizumab at some stage in their care, and this may compound late rectal morbidity.
Published series in prostate brachytherapy report late grades 2 and 3 GI complications ranging from 3.7% to 18% and ,1-8%. 20 Therefore, following 50.4-Gy EBRT to the pelvis, a prostate brachytherapy boost is an attractive treatment paradigm as reported by Qiu et al. 5 131 Cs with a photon energy similar to iodine-125 but with a significantly shorter half-life of 9.6 days compared with 59.4 days may be an effective method of delivering a prostate boost in suitable patients, and with a shorter half-life, it is more favourable for pre-operative use. If 131 Cs seeds are not available then iodine or palladium brachytherapy is not recommended. A technique not explored in case series to date is EBRT with a single-fraction high-dose-rate brachytherapy boost. 21 This technique would remove the radiation protection hazard for surgeons and may reduce the delay in proceeding to surgery that was associated with seed implants.
Patient 3 experienced an anastomotic stricture. This may have been the result of an overlap with the high-dose region of the prostate boost. "Anastomotic Planning" should be undertaken in Table 2 . Acute and late radiotherapy toxicity (maximum reported grade) consultation with the surgeon to determine the likely location of the anastomosis in relation to the high-dose region of the prostate boost. Clearly for patients who will require APR, there will not be an anastomosis, and this complication cannot occur.
CONCLUSION
EBRT for synchronous rectal and prostate cancers is relatively straightforward to plan and deliver. It appears to be well tolerated in the acute setting, but there is potential for significant late rectal morbidity. The required dose can be delivered to both tumour sites by multiple-phase EBRT or EBRT and a brachytherapy boost. Not all patients benefit from delivery of the standard high dose to the prostate. Despite small numbers, our series highlights important considerations in this unusual cohort.
